WEE1 and acute myeloid leukemia: In acute myeloid leukemia, combination treatment of CUDC-907 with Wee1 inhibitor adavosertib showed a synergistic effect in both AML cell lines and primary specimens by enhancing the adavosertib-initiated DNA damage [22].